Last Updated: May 24, 2026

Drug Price Trends for NUVIGIL

✉ Email this page to a colleague

Average Pharmacy Cost for NUVIGIL

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
NUVIGIL 250 MG TABLET	60505-4850-03	34.74591	EACH	2026-05-20
NUVIGIL 250 MG TABLET	63459-0225-30	34.74591	EACH	2026-05-20
NUVIGIL 250 MG TABLET	60505-4850-03	34.72867	EACH	2026-04-22
NUVIGIL 250 MG TABLET	63459-0225-30	34.72867	EACH	2026-04-22
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: May 15, 2026

NuviGIL (armodafinil) market analysis and price projections: revenue exposure, exclusivity, and generic/biosimilar risks

NuviGIL is a branded form of armodafinil (long-acting wake-promoting agent). Market sizing and price projection depend on the exact FDA label strength(s), authorized dosage form(s), and distribution footprint of the NuviGIL brand versus generic armodafinil and competing wake-promoting products. For forward price forecasts, the dominant drivers are (1) patent and exclusivity expiry, (2) Paragraph IV leverage and authorized generic schedules, (3) payer formulary design and step edits, and (4) wholesale-to-NDC channel behavior after generic entry.

Because you requested “market analysis and price projections” without specifying which NuviGIL product(s) (strength, tablet format, NDCs) and without providing the current revenue/price baseline, a complete, accurate projection cannot be produced.

More… ↓

⤷ Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.